ArticleOncoscience2014
Altered metabolic pathways in clear cell renal cell carcinoma: A meta-analysis and validation study focused on the deregulated genes and their associated networks.
Article in Oncoscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Multi-omics data integration for enhanced cancer subtyping via interactive multi-kernel learning.Briefings in bioinformatics · 2025Article
- The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression.Cancer immunology, immunotherapy : CII · 2023Article
- Prediction of Distant Metastases in Patients with Kidney Cancer Based on Gene Expression and Methylation Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Differential Activation of NRF2 Signaling Pathway in Renal-Cell Carcinoma Caki Cell Lines.Biomedicines · 2023Article
- Does the Urinary Proteome Reflect ccRCC Stage and Grade Progression?Diagnostics (Basel, Switzerland) · 2021Article
- METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression.Journal of translational medicine · 2021Article
- MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma.BMC medical genomics · 2021Article
- ABAT and ALDH6A1, regulated by transcription factor HNF4A, suppress tumorigenic capability in clear cell renal cell carcinoma.Journal of translational medicine · 2020Article
- The Genes-Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer.Diagnostics (Basel, Switzerland) · 2020Article
- Transferrin receptor-involved HIF-1 signaling pathway in cervical cancer.Cancer gene therapy · 2019Article
- Identification of a lncRNA‑associated competing endogenous RNA‑regulated network in clear cell renal cell carcinoma.Molecular medicine reports · 2019Article
- Recognition of early and late stages of bladder cancer using metabolites and machine learning.Metabolomics : Official journal of the Metabolomic Society · 2019Article
- Primary Tumor Site Specificity is Preserved in Patient-Derived Tumor Xenograft Models.Frontiers in genetics · 2019Article
- Article
- miR-199b-5p serves as a tumor suppressor in renal cell carcinoma.Experimental and therapeutic medicine · 2018Article
- The downregulated long noncoding RNAOncoTargets and therapy · 2018Article
- A comprehensive analysis of cancer-driving mutations and genes in kidney cancer.Oncology letters · 2017Article
- Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.EBioMedicine · 2017Article
- High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma.Therapeutics and clinical risk management · 2017Article
- NicotinamideInternational journal of tryptophan research : IJTR · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is the predominant subtype of renal cell carcinoma (RCC). It is one of the most therapy-resistant carcinomas, responding very poorly or not at all to radiotherapy, hormonal therapy and chemotherapy. A more comprehensive understanding of the deregulated pathways in ccRCC can lead to the development of new therapies and prognostic markers. We performed a meta- analysis of 5 publicly available gene expression datasets and identified a list of co- deregulated genes, for which we performed extensive bioinformatic analysis coupled with experimental validation on the mRNA level. Gene ontology enrichment showed that many proteins are involved in response to hypoxia/oxygen levels and positive regulation of the VEGFR signaling pathway. KEGG analysis revealed that metabolic pathways are mostly altered in ccRCC. Similarly, Ingenuity Pathway Analysis showed that the antigen presentation, inositol metabolism, pentose phosphate, glycolysis/gluconeogenesis and fructose/mannose metabolism pathways are altered in the disease. Cellular growth, proliferation and carbohydrate metabolism, were among the top molecular and cellular functions of the co-deregulated genes. qRT-PCR validated the deregulated expression of several genes in Caki-2 and ACHN cell lines and in a cohort of ccRCC tissues. NNMT and NR3C1 increased expression was evident in ccRCC biopsies from patients using immunohistochemistry. ROC curves evaluated the diagnostic performance of the top deregulated genes in each dataset. We show that metabolic pathways are mostly deregulated in ccRCC and we highlight those being most responsible in its formation. We suggest that these genes are candidate predictive markers of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.